查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
非何杰金氏淋巴瘤市場：KOL洞察
市場調查報告書
商品編碼
1773135

非何杰金氏淋巴瘤市場：KOL洞察

KOL Insight - Non-Hodgkin Lymphoma
出版日期: | 出版商: FirstWord Group | 英文 | 商品交期: 最快1-2個工作天內

價格
簡介目錄

本報告深入探討了非何杰金氏淋巴瘤（NHL）標靶治療的持續發展，並對目前和未來的治療途徑提供了詳細的見解。報告探討了主要上市藥物類別的療效和安全性比較，包括嵌合抗原受體T細胞療法、雙特異性抗體、抗體-藥物偶聯物、單株抗體和BTK抑制劑。報告中還探討了新型療法在中後期臨床開發中的潛在影響，並重點介紹了可能影響未來處方趨勢的關鍵臨床試驗。本報告探討了未來幾年非何杰金氏淋巴瘤治療模式的變化，並重點介紹了非何杰金氏淋巴瘤面臨的挑戰和機會。

關鍵問題

  • 1.CAR-T 細胞療法目前是許多地區治療瀰漫大B細胞淋巴瘤（DLBCL）、濾泡性淋巴瘤（FL）和套細胞淋巴瘤（MCL）的主要手段，但在可預見的未來，其應用前景將如何發展？
  • 2.Roche和AbbVie/Genmab（以及歐洲的再生元）的T 細胞結合雙特異性抗體現已獲準用於治療濾泡性淋巴瘤（FL），KOL 預計治療方案將如何發展？
  • 3.Roche的Columvi 現已在歐洲獲準（基於 STARGLO），且多項雙特異性抗體在二線 DLBCL 治療中的臨床試驗進行中，這種療法能否成為標準治療方案？
  • 4.再生元的雙特異性抗體 Ordospono 如何被非何杰金氏淋巴瘤專家接受？
  • 5.KOL 對Merck公司用於治療瀰漫性大B細胞淋巴瘤（DLBCL）的抗 ROR1 抗體偶聯藥物 zilovertamab vedotin 有何期待？
  • 6.AstraZeneca的Calquence 最近獲得 FDA 和 EMA 的批准延期，可將其添加到套細胞淋巴瘤（MCL）的一線治療中，而BeiGene的Brukinsa 參與 MANGROVE 臨床試驗。專家如何評估 BTK 抑制劑在這類第一線治療的前景？
  • 7.B 細胞非何杰金氏淋巴瘤的治療未來將如何發展？

主要品牌

  • Yescarta (axicabtagene ciloleucel)
  • Kymriah (tisagenlecleucel)
  • Breyanzi (lisocabtagene maraleucel)
  • Tecartus (brexucabtagene autoleucel)
  • Polivy (polatuzumab vedotin)
  • Zynlonta (loncastuximab tesirine)
  • Monjuvi/Minjuvi (tafasitamab)
  • Lunsumio (mosunetuzumab)
  • Epkinly/Tepkinly (epcoritamab)
  • Columvi (glofitamab)
  • Ordspono (odronextamab)
  • Brukinsa (zanubrutinib)
  • Calquence (acalabrutinib)
  • Imbruvica (ibrutinib)
  • Jaypirca (pirtobrutinib)
  • nemtabrutinib (MK-1026)
  • AZD0486 (TNB-486)
  • Adcetris (brentuximab vedotin)
  • zilovertamab vedotin (MK-2140)
  • golcadomide
  • sonrotoclax

部分參與專家名單

  • 美國萊文癌症研究所淋巴瘤主任
  • 美國莎拉‧坎農研究中心血液學研究主任
  • 美國邁阿密大學血液學教授兼淋巴瘤負責人
  • 英國牛津大學醫院NHS基金會淋巴系統惡性腫瘤專科血液科顧問醫生
  • 法國古斯塔夫魯西研究所醫學主任兼腫瘤血液科資深執業醫師
  • 法國克萊蒙奧弗涅大學CHU Estaing血液學與細胞療法教授

方法論

治療趨勢報告是透過對全球領先的KOL（關鍵意見領袖）的深入訪談彙編而成。致力於為關鍵疾病領域的當前和未來治療格局提供領導者視角。關鍵意見領袖（KOL）的甄選是基於嚴格的篩選標準，包括全球聲譽、臨床專業知識以及在治療領域的影響力。每次訪談都附有精心設計的討論指南。這些指南由與關鍵意見領袖合作制定，並由行業專家進行同行評審，以確保所提問題全面且與當前市場動態相關。會在每份報告發布後持續進行12個月的市場監測，並及時提供來自關鍵意見領袖關於重要新聞事件、市場變化和市場發展的最新消息。

報告有何特別之處？

FirstWord Reports 是值得信賴的行業領導者，致力於製藥業，為生物製藥專業人士和決策者提供詳細且可操作的洞察。深厚的行業知識使能夠提供相關且有價值的洞察，幫助掌握新興趨勢並有效解決複雜挑戰。憑藉廣泛的研究以及來自領先專家和關鍵意見領袖的獨立、公正的見解，報告能夠提供所需的準確性和可靠性。獨家獲取其他地方無法獲得的採訪和資料，以及持續的市場監測，確保全面了解市場動態。報告涵蓋 40 多個活躍疾病領域，匯集醫生情報（包括 KOL 洞察和定量醫生調查），以及行業專家對醫療事務、數位醫療、銷售與市場營銷、市場准入及其他領域問題的看法，助做出更明智的資料驅動決策，在快速變化的行業中保持競爭力。

簡介目錄

This comprehensive report delves into the evolving landscape of targeted therapies for Non-Hodgkin Lymphoma (NHL), providing you with in-depth insights into current and future treatment pathways. It explores the comparative efficacy and safety profiles of key marketed drug classes, including CAR T-cell therapies, bispecific antibodies, antibody-drug conjugates, monoclonal antibodies, and BTK inhibitors. The report also examines the potential impact of novel therapies in mid-to-late stage clinical development and highlights significant ongoing clinical trials that could shape future prescribing trends. This report offers a nuanced understanding of how treatment paradigms for NHL are likely to evolve over the next few years, identifying both challenges and opportunities in the field.

Key Questions Answered:

  • 1. CAR T-cell therapies are now a mainstay in DLBCL, FL and MCL in many localities, but how is their use expected to evolve in the foreseeable future?
  • 2. With T-cell-engaging bispecific antibodies from Roche and AbbVie/Genmab (and also Regeneron in Europe) now approved for FL, how do KOLs expect the treatment algorithm to evolve?
  • 3. With Roche's Columvi now approved in Europe (based on STARGLO), and several other trials of bispecifics in second-line DLBCL underway, could this modality become a standard of care in this setting?
  • 4. How is Regeneron's bispecific antibody Ordspono perceived by NHL specialists, and could it still find a role in an increasingly competitive market despite its relatively late entry?
  • 5. What are KOL expectations for Merck & Co.'s pipeline anti-ROR1 antibody-drug conjugate zilovertamab vedotin in the treatment of DLBCL?
  • 6. With the recent FDA and EMA extended approval for AstraZeneca's Calquence to include first-line MCL and the MANGROVE trial of BeiGene's Brukinsa underway, how do the experts weigh up the prospects for BTK inhibitors in this frontline setting?
  • 7. How might the treatment landscape for B-cell NHL evolve in the coming years?

Key Brands:

  • Yescarta (axicabtagene ciloleucel)
  • Kymriah (tisagenlecleucel)
  • Breyanzi (lisocabtagene maraleucel)
  • Tecartus (brexucabtagene autoleucel)
  • Polivy (polatuzumab vedotin)
  • Zynlonta (loncastuximab tesirine)
  • Monjuvi/Minjuvi (tafasitamab)
  • Lunsumio (mosunetuzumab)
  • Epkinly/Tepkinly (epcoritamab)
  • Columvi (glofitamab)
  • Ordspono (odronextamab)
  • Brukinsa (zanubrutinib)
  • Calquence (acalabrutinib)
  • Imbruvica (ibrutinib)
  • Jaypirca (pirtobrutinib)
  • nemtabrutinib (MK-1026)
  • AZD0486 (TNB-486)
  • Adcetris (brentuximab vedotin)
  • zilovertamab vedotin (MK-2140)
  • golcadomide
  • sonrotoclax

Partial List of Participating Experts:

  • Director, Lymphoma Division, Levine Cancer Institute, USA
  • Medical Director of Hematology Research, Sarah Cannon Research, USA
  • Professor of Medicine and Chief of Lymphoma Section at Division of Hematology, University of Miami, USA
  • Consultant Haematologist specialising in lymphoid malignancies, Oxford University Hospitals NHS Foundation Trust, UK
  • Medical Director and Senior Practitioner in onco-hematology, Gustave Roussy Institute, France
  • Professor, Service d'Hematologie et de Therapie Cellulaire, CHU Estaing, Universite Clermont Auvergne, France

Methodology:

Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.